Last reviewed · How we verify

Irbesartan/Atorvastatin B

Hanmi Pharmaceutical Company Limited · Phase 3 active Small molecule

Irbesartan/Atorvastatin B is a Angiotensin II receptor antagonist / HMG-CoA reductase inhibitor combination Small molecule drug developed by Hanmi Pharmaceutical Company Limited. It is currently in Phase 3 development for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy. Also known as: HCP0912 B.

Irbesartan/Atorvastatin B is a fixed-dose combination that lowers blood pressure via angiotensin II receptor blockade and reduces cholesterol via HMG-CoA reductase inhibition.

Irbesartan/Atorvastatin B is a fixed-dose combination that lowers blood pressure via angiotensin II receptor blockade and reduces cholesterol via HMG-CoA reductase inhibition. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.

At a glance

Generic nameIrbesartan/Atorvastatin B
Also known asHCP0912 B
SponsorHanmi Pharmaceutical Company Limited
Drug classAngiotensin II receptor antagonist / HMG-CoA reductase inhibitor combination
TargetAT1 receptor / HMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Irbesartan blocks the angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone secretion to lower blood pressure. Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and cardiovascular risk. The combination addresses two major cardiovascular risk factors simultaneously.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Irbesartan/Atorvastatin B

What is Irbesartan/Atorvastatin B?

Irbesartan/Atorvastatin B is a Angiotensin II receptor antagonist / HMG-CoA reductase inhibitor combination drug developed by Hanmi Pharmaceutical Company Limited, indicated for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.

How does Irbesartan/Atorvastatin B work?

Irbesartan/Atorvastatin B is a fixed-dose combination that lowers blood pressure via angiotensin II receptor blockade and reduces cholesterol via HMG-CoA reductase inhibition.

What is Irbesartan/Atorvastatin B used for?

Irbesartan/Atorvastatin B is indicated for Hypertension with dyslipidemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.

Who makes Irbesartan/Atorvastatin B?

Irbesartan/Atorvastatin B is developed by Hanmi Pharmaceutical Company Limited (see full Hanmi Pharmaceutical Company Limited pipeline at /company/hanmi-pharmaceutical-company-limited).

Is Irbesartan/Atorvastatin B also known as anything else?

Irbesartan/Atorvastatin B is also known as HCP0912 B.

What drug class is Irbesartan/Atorvastatin B in?

Irbesartan/Atorvastatin B belongs to the Angiotensin II receptor antagonist / HMG-CoA reductase inhibitor combination class. See all Angiotensin II receptor antagonist / HMG-CoA reductase inhibitor combination drugs at /class/angiotensin-ii-receptor-antagonist-hmg-coa-reductase-inhibitor-combination.

What development phase is Irbesartan/Atorvastatin B in?

Irbesartan/Atorvastatin B is in Phase 3.

What are the side effects of Irbesartan/Atorvastatin B?

Common side effects of Irbesartan/Atorvastatin B include Dizziness, Fatigue, Muscle pain (myalgia), Elevated liver enzymes, Hyperkalemia.

What does Irbesartan/Atorvastatin B target?

Irbesartan/Atorvastatin B targets AT1 receptor / HMG-CoA reductase and is a Angiotensin II receptor antagonist / HMG-CoA reductase inhibitor combination.

Related